Trial Profile
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary) ; AS01B; AS01E
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 28 Jun 2022 According to a GlaxoSmithKline media release, based on data from six clinical trials (NCT01610414, NCT01798056, NCT01767467, NCT00920218, NCT01165203), the company has submitted regulatory application to the Japanese MHLW for Shingrix for the prevention of shingles in adults aged 18 years and older who are at increased risk. This includes individuals with immunodeficiency or immunosuppression caused by known disease or therapy.
- 27 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.